"label","uuid:ID","instanceType","rationale","id","name","description"
"","7269188b-58a7-4459-812c-148a553c7f94","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","Study Design 1","The main design for the study"
